CAR-T Meeting 2022 | Strategies to overcome the current obstacles in CAR-T manufacturing
Christian Buchholz, PhD, Paul-Ehrlich-Institut, Langen, Germany, comments on strategies to reduce the manufacturing time of chimeric antigen receptor T-cell (CAR-T) therapies, focusing on in vivo CAR-T generation. Currently, CAR-T manufacturing is a complex, costly and time-consuming process. Strategies to reduce the manufacturing time and make CAR-T therapy available to a larger number of patients include producing off-the-shelf allogeneic CAR-Ts, manufacturing CAR-Ts directly at the hospital, and developing new manufacturing platforms. Another approach is in vivo CAR-T generation, which consists in injecting a vector that delivers the CAR-T into the patient using a viral vector or lipid nanoparticles. So far, this promising off-the-shelf approach has been successful in humanized mice, but it is necessary to evaluate it in larger animal models. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
